ReviewMaterials today. Bio2025
Advances in natural product-based nanoparticles for the treatment of acute lung injury.
Review in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CuBioactive materials · 2026Article
- miRNAs-neutrophil axis: novel insights into acute lung injury and chronic inflammatory lung diseases.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute lung injury (ALI) is a rapid-onset inflammatory pathology in pulmonary tissue induced by multiple causative agents. ALI usually develops rapidly within hours to days after an acute episode, and despite the development of aggressive therapeutic measures, the prognosis of patients with ALI remains poor. Currently, the clinical treatment of ALI is based on supportive therapy, and with the advancement of technology, many natural products have been used for the treatment of ALI because of their advantages, such as lower drug resistance and more abundant sources; however, shortcomings such as its lower targeting limit its further clinical application. The use of nanotechnology may be an effective way to address these issues. The combination of natural products and nanotechnology offers the possibility of solving the problems of their low bioavailability and poor water solubility, which is expected to promote their application in the field of ALI therapy. Natural product-based nanomaterials can control the progression of ALI through mechanisms such as modulating immune responses and reducing tissue inflammation. This review focuses on the roles of natural product-based nanoparticles in the treatment of ALI and further elaborates on the problems and challenges faced by natural product-based nanoparticles in the effective clinical treatment of ALI.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.